BR112013022416A2 - derivados de sec-hidróxi-ciclohexila como inibidores de hsl para o tratamento de diabetes - Google Patents
derivados de sec-hidróxi-ciclohexila como inibidores de hsl para o tratamento de diabetesInfo
- Publication number
- BR112013022416A2 BR112013022416A2 BR112013022416A BR112013022416A BR112013022416A2 BR 112013022416 A2 BR112013022416 A2 BR 112013022416A2 BR 112013022416 A BR112013022416 A BR 112013022416A BR 112013022416 A BR112013022416 A BR 112013022416A BR 112013022416 A2 BR112013022416 A2 BR 112013022416A2
- Authority
- BR
- Brazil
- Prior art keywords
- diabetes
- treatment
- sec
- hydroxy
- hsl
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 102000000019 Sterol Esterase Human genes 0.000 abstract 1
- 108010055297 Sterol Esterase Proteins 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
derivados de sec-hidróxi-ciclohexila como inibidores de hsl para o tratamento de diabetes a invenção fornece compostos novos tendo a fórmula geral (i) em que r^ 1^, r^ 2^ e r^ 3^ são como descritos aqui, e composições incluindo os compostos. o uso dos compostos como inibidores de lípase sensível a hormônio (hsl) para o tratamento de doenças como diabetes e síndrome metabólica também é revelado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11158386 | 2011-03-16 | ||
PCT/EP2012/054307 WO2012123432A1 (en) | 2011-03-16 | 2012-03-13 | Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013022416A2 true BR112013022416A2 (pt) | 2016-12-13 |
Family
ID=45812793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013022416A BR112013022416A2 (pt) | 2011-03-16 | 2012-03-13 | derivados de sec-hidróxi-ciclohexila como inibidores de hsl para o tratamento de diabetes |
Country Status (11)
Country | Link |
---|---|
US (1) | US8722721B2 (pt) |
EP (1) | EP2686299A1 (pt) |
JP (1) | JP6117709B2 (pt) |
KR (1) | KR20140022840A (pt) |
CN (1) | CN103415506B (pt) |
BR (1) | BR112013022416A2 (pt) |
CA (1) | CA2830126A1 (pt) |
HK (1) | HK1190706A1 (pt) |
MX (1) | MX339513B (pt) |
RU (1) | RU2013142647A (pt) |
WO (1) | WO2012123432A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
US8809384B2 (en) * | 2011-03-25 | 2014-08-19 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
CN104788360B (zh) * | 2015-03-30 | 2017-07-25 | 曲阜师范大学 | 3‑砜基螺环三烯酮类化合物及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10247680B4 (de) * | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
EP1529528A1 (en) * | 2003-11-07 | 2005-05-11 | Universitätsklinikum Freiburg | 2-pyrrolidone derivatives and their use in protecting mammalian cells against oxidation stress |
US20070208001A1 (en) * | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
DK2035379T3 (da) | 2006-04-25 | 2010-09-06 | Lilly Co Eli | Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1 |
US8329904B2 (en) * | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
US8440710B2 (en) * | 2009-10-15 | 2013-05-14 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
TW201118069A (en) * | 2009-10-28 | 2011-06-01 | Lundbeck & Co As H | Spirolactam derivatives and uses of same |
US8389539B2 (en) * | 2009-12-01 | 2013-03-05 | Hoffman-La Roche Inc. | Azacyclic derivatives |
US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
EP2569296A1 (en) | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
-
2012
- 2012-03-08 US US13/414,753 patent/US8722721B2/en not_active Expired - Fee Related
- 2012-03-13 CN CN201280012084.XA patent/CN103415506B/zh not_active Expired - Fee Related
- 2012-03-13 RU RU2013142647/04A patent/RU2013142647A/ru not_active Application Discontinuation
- 2012-03-13 MX MX2013010006A patent/MX339513B/es active IP Right Grant
- 2012-03-13 EP EP12708036.4A patent/EP2686299A1/en not_active Withdrawn
- 2012-03-13 WO PCT/EP2012/054307 patent/WO2012123432A1/en active Application Filing
- 2012-03-13 KR KR1020137027122A patent/KR20140022840A/ko not_active Application Discontinuation
- 2012-03-13 JP JP2013558403A patent/JP6117709B2/ja active Active
- 2012-03-13 CA CA2830126A patent/CA2830126A1/en not_active Abandoned
- 2012-03-13 BR BR112013022416A patent/BR112013022416A2/pt not_active IP Right Cessation
-
2014
- 2014-04-18 HK HK14103756.2A patent/HK1190706A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP6117709B2 (ja) | 2017-04-19 |
HK1190706A1 (en) | 2014-07-11 |
MX2013010006A (es) | 2013-12-06 |
MX339513B (es) | 2016-05-30 |
JP2014508178A (ja) | 2014-04-03 |
CN103415506A (zh) | 2013-11-27 |
US20120238613A1 (en) | 2012-09-20 |
CA2830126A1 (en) | 2012-09-20 |
CN103415506B (zh) | 2015-08-05 |
RU2013142647A (ru) | 2015-04-27 |
KR20140022840A (ko) | 2014-02-25 |
US8722721B2 (en) | 2014-05-13 |
EP2686299A1 (en) | 2014-01-22 |
WO2012123432A1 (en) | 2012-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
BR112014010644A2 (pt) | novos derivados de aril-quinolina | |
BRPI1016219B8 (pt) | composto indazol substituído com oxazol, e, composição farmacêutica | |
BR112015022804A2 (pt) | novos derivados de octahidro-pirrol [3,4-c]-pirrol e seus análogos como inibidores de autotaxina | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
EA201690473A1 (ru) | Комбинированный состав двух противовирусных соединений | |
BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
BR112012017269A2 (pt) | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos | |
BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
SV2011003809A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
BR112012026147A2 (pt) | espiroderivados azacíclicos como inibidores de hsl | |
BR112014029139A8 (pt) | compostos inibidores da atividade de catecol o-metiltransferase | |
BR112014003693A2 (pt) | amino quinazolinas como inibidores de quinase | |
MA33937B1 (fr) | Composes pyrazole comme antagonistes du recepteur crth2 | |
BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
CR11483A (es) | Inhibidores de peptido desformilasa | |
BR112013031405A2 (pt) | piridopirazinas substituídas como novos inibidores de syk | |
CL2012000937A1 (es) | Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad. | |
BR112013014782A2 (pt) | composição, método para o controle de vegetação indesejada, uso de composições, método para proteger a atividade fitotóxica de uma benzoxazinona de fórmula i e método de proteção | |
ECSP13012600A (es) | CO-cristales y Sales de Inhibidores de CCR3 | |
BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
EA201170828A1 (ru) | Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза | |
CR20170513A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |